Patients with progressive fibrosing interstitial lung diseases who received nintedanib (Ofev®) treatment for one year had a slower decline in lung function than those who received placebo, reports a new phase 3 study.
Blocking the activity of interleukin-11 (IL-11) — a molecule that mediates immune and inflammatory responses — reverses tissue scarring, or fibrosis, in the lungs of mice, a study has found.
Different combinations of medications to manage comorbidities may influence disease progression in people with idiopathic pulmonary fibrosis, a study suggests.
Weight loss is more common among patients with idiopathic pulmonary fibrosis who are being treated with Ofev (nintedanib), and also among those at advanced stages of the disease.
A mutation in the gene ZCCHC8 leads to abnormalities in the structure of telomeres, the protective caps at the end of the DNA, contributing to the development of idiopathic pulmonary fibrosis, a new study shows.
